T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.
a Department of Hematology, Institute of Hematology , The First Affiliated Hospital, Zhejiang University , Hangzhou , China.|b Key Laboratory of Hematopoietic Malignancies Zhejiang Province , Hangzhou , China.
Dongmei
D
Wang
a Department of Hematology, Institute of Hematology , The First Affiliated Hospital, Zhejiang University , Hangzhou , China.|b Key Laboratory of Hematopoietic Malignancies Zhejiang Province , Hangzhou , China.
Hanzhang
H
Pan
a Department of Hematology, Institute of Hematology , The First Affiliated Hospital, Zhejiang University , Hangzhou , China.|b Key Laboratory of Hematopoietic Malignancies Zhejiang Province , Hangzhou , China.
Yungui
Y
Wang
D000483:Alleles; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009154:Mutation; D017354:Point Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D054730:Protein Interaction Domains and Motifs / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology*; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl